Compare Stocks → You’re invited: Biggest crypto event of 2024 (From InvestorPlace) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ATNFNASDAQ:ATXINASDAQ:BNTCNASDAQ:ONCS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNF180 Life Sciences$1.83-4.2%$3.08$1.33▼$27.93$1.63M0.44137,403 shs90,580 shsATXIAvenue Therapeutics$0.13$0.15$0.11▼$1.25$5.96M-0.244.59 million shs290,143 shsBNTCBenitec Biopharma$6.82+42.1%$4.75$1.86▼$9.01$17.66M1.0364,620 shs3.52 million shsONCSOncoSec Medical$0.52$0.18▼$20.46$1.26M1.992.22 million shs52.49 million shs7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNF180 Life Sciences-4.19%-21.79%-41.53%-52.44%-92.11%ATXIAvenue Therapeutics-0.37%-4.67%-15.88%-3.93%-87.54%BNTCBenitec Biopharma+42.08%+9.47%+34.52%+139.30%+74.42%ONCSOncoSec Medical0.00%0.00%0.00%0.00%-72.00%You’re invited: Biggest crypto event of 2024 (Ad)During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.Just click here to sign up and be among the first to get it.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATNF180 Life SciencesN/AN/AN/AN/AN/AN/AN/AN/AATXIAvenue TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ABNTCBenitec Biopharma1.4723 of 5 stars3.53.00.00.02.30.80.0ONCSOncoSec MedicalN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATNF180 Life SciencesN/AN/AN/AN/AATXIAvenue Therapeutics3.00BuyN/AN/ABNTCBenitec Biopharma3.00Buy$10.0046.63% UpsideONCSOncoSec MedicalN/AN/AN/AN/ACurrent Analyst RatingsLatest ONCS, BNTC, ATXI, and ATNF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/15/2024BNTCBenitec BiopharmaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$8.00 ➝ $10.001/24/2024BNTCBenitec BiopharmaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$6.00 ➝ $8.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATNF180 Life SciencesN/AN/AN/AN/A($0.24) per shareN/AATXIAvenue TherapeuticsN/AN/AN/AN/A$0.03 per shareN/ABNTCBenitec Biopharma$80K220.80N/AN/A$0.12 per share56.83ONCSOncoSec MedicalN/AN/AN/AN/A$3.42 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATNF180 Life Sciences-$19.93MN/A0.00∞N/AN/A-320.26%-112.07%5/20/2024 (Estimated)ATXIAvenue Therapeutics-$10.38M-$1.27N/A∞N/AN/AN/A-335.11%5/10/2024 (Estimated)BNTCBenitec Biopharma-$19.56M-$2.56N/A∞N/AN/A-204.34%-142.81%5/20/2024 (Estimated)ONCSOncoSec Medical-$34.18M-$15.29N/AN/AN/AN/A-868.29%-160.61%N/ALatest ONCS, BNTC, ATXI, and ATNF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/18/2024Q4 2023ATXIAvenue TherapeuticsN/A$0.56+$0.56$0.56N/AN/A2/13/2024Q2 2024BNTCBenitec BiopharmaN/A-$2.64-$2.64-$2.64N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATNF180 Life SciencesN/AN/AN/AN/AN/AATXIAvenue TherapeuticsN/AN/AN/AN/AN/ABNTCBenitec BiopharmaN/AN/AN/AN/AN/AONCSOncoSec MedicalN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATNF180 Life SciencesN/A0.720.72ATXIAvenue TherapeuticsN/A1.551.55BNTCBenitec Biopharma0.013.623.62ONCSOncoSec MedicalN/A0.890.89OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATNF180 Life Sciences4.07%ATXIAvenue Therapeutics17.34%BNTCBenitec Biopharma52.19%ONCSOncoSec Medical8.69%Insider OwnershipCompanyInsider OwnershipATNF180 Life Sciences4.10%ATXIAvenue Therapeutics1.80%BNTCBenitec Biopharma4.30%ONCSOncoSec Medical1.32%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableATNF180 Life Sciences5850,000818,000No DataATXIAvenue Therapeutics344.26 million43.46 millionNot OptionableBNTCBenitec Biopharma182.59 million2.48 millionNo DataONCSOncoSec Medical404.55 million4.49 millionNot OptionableONCS, BNTC, ATXI, and ATNF HeadlinesSourceHeadlineIs OncoSec Medical Inc (ONCSQ) Stock a Good Investment?aaii.com - June 29 at 2:37 AMONCS - OncoSec Medical Incorporatedfinance.yahoo.com - June 24 at 8:41 AM0 analysts rank ONCS stock as an Overweightknoxdaily.com - June 23 at 6:54 PMWhy Is OncoSec Medical (ONCS) Stock Up 100% Today?markets.businessinsider.com - June 23 at 8:53 AMWhy John Wiley & Sons Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Sessionmsn.com - June 15 at 2:49 PMWhy Is OncoSec Medical (ONCS) Stock Down 48% Today?msn.com - June 15 at 9:48 AMOncoSec Announces Closing of $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rulesfinance.yahoo.com - May 18 at 8:59 PMOncoSec Medical plunges 35% lower on sale of 1.4M shares of common stockmsn.com - May 16 at 4:15 PMOncoSec Announces $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rulesfinance.yahoo.com - May 16 at 4:15 PMOncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical programfinance.yahoo.com - May 16 at 9:56 AMOncoSec Receives $3.49 Million to Strengthen its Balance Sheet After Selling its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Authority NOL Programfinance.yahoo.com - April 27 at 8:26 AMOncoSec Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rulesfinance.yahoo.com - April 11 at 5:48 PMWhy OncoSec Medical Shares Are Soaring Todaymsn.com - April 10 at 4:15 PMOncoSec Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rulesfinance.yahoo.com - April 10 at 4:15 PMOncoSec Medical Inc (ONCS) is lower by 6.15% Tuesday In Premarket Tradingbenzinga.com - April 6 at 7:57 PMOncoSec Shares Disappointing Results From Skin Cancer Combo Therapy Trial, Sets Stage For Neoadjuvant Setting Studyfinance.yahoo.com - April 3 at 3:57 PMOncoSec crashes ~60% after TAVO-EP, Keytruda combo fails phase 2 skin cancer trialmsn.com - April 3 at 10:57 AMOncoSec Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO™-EP in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatmentfinance.yahoo.com - April 3 at 10:57 AMOncoSec Medical Withdraws Planned Offering, Shares Rise Over 50%marketwatch.com - March 1 at 8:56 AMWhy is OncoSec Medical (ONCS) Stock Up 91% Today?msn.com - March 1 at 8:56 AMONCS.OQ - | Stock Price & Latest News | Reutersreuters.com - January 16 at 7:08 PMOncoSec Medical Stock (NASDAQ:ONCS), Quotes and News Summarybenzinga.com - January 5 at 3:51 PMPeering Into OncoSec Medical's Recent Short Interestmsn.com - December 8 at 5:34 PMOncoSec to Present at the RHK Capital Disruptive Growth Conference on December 6, 2022finance.yahoo.com - December 5 at 1:28 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany Descriptions180 Life SciencesNASDAQ:ATNF180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.Avenue TherapeuticsNASDAQ:ATXIAvenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of rare and neurologic diseases in the United States. Its lead product candidate includes AJ201, which in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous (IV) Tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. Avenue Therapeutics, Inc. was incorporated in 2015 and is based in Tampa, Florida.Benitec BiopharmaNASDAQ:BNTCBenitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.OncoSec MedicalNASDAQ:ONCSOncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.